{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T12:17:34Z","timestamp":1777551454011,"version":"3.51.4"},"reference-count":119,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2019,7,1]],"date-time":"2019-07-01T00:00:00Z","timestamp":1561939200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,7,1]],"date-time":"2019-07-01T00:00:00Z","timestamp":1561939200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["bmn.com","cell.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Trends in Microbiology"],"published-print":{"date-parts":[[2019,7]]},"DOI":"10.1016\/j.tim.2019.02.009","type":"journal-article","created":{"date-parts":[[2019,4,10]],"date-time":"2019-04-10T11:21:59Z","timestamp":1554895319000},"page":"593-606","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":33,"title":["The Promise of Long-Acting Antiretroviral Therapies: From Need to Manufacture"],"prefix":"10.1016","volume":"27","author":[{"given":"Howard E.","family":"Gendelman","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"JoEllyn","family":"McMillan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aditya N.","family":"Bade","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Benson","family":"Edagwa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bhavesh D.","family":"Kevadiya","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.tim.2019.02.009_bb0005","doi-asserted-by":"crossref","first-page":"469","DOI":"10.4155\/tde.15.4","article-title":"Nanoformulation strategies for the enhanced oral bioavailability of antiretroviral therapeutics","volume":"6","author":"Tatham","year":"2015","journal-title":"Ther. Deliv."},{"key":"10.1016\/j.tim.2019.02.009_bb0010","doi-asserted-by":"crossref","first-page":"1499","DOI":"10.1016\/S0140-6736(17)31917-7","article-title":"Long-acting intramuscular cabotegravir and rilpivirine in adults with HIV-1 infection (LATTE-2): 96-week results of a randomised, open-label, phase 2b, non-inferiority trial","volume":"390","author":"Margolis","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.tim.2019.02.009_bb0015","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1097\/COH.0000000000000474","article-title":"Rilpivirine long-acting for the prevention and treatment of HIV infection","volume":"13","author":"Ferretti","year":"2018","journal-title":"Curr. Opin. HIV AIDS"},{"key":"10.1016\/j.tim.2019.02.009_bb0020","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1097\/COH.0000000000000164","article-title":"Formulation and pharmacology of long-acting rilpivirine","volume":"10","author":"Williams","year":"2015","journal-title":"Curr. Opin. HIV AIDS"},{"key":"10.1016\/j.tim.2019.02.009_bb0025","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1097\/COH.0000000000000002","article-title":"Long-acting injectable antiretrovirals for HIV treatment and prevention","volume":"8","author":"Spreen","year":"2013","journal-title":"Curr. Opin. HIV AIDS"},{"key":"10.1016\/j.tim.2019.02.009_bb0030","doi-asserted-by":"crossref","first-page":"1807","DOI":"10.2217\/nnm.12.214","article-title":"Long-acting parenteral nanoformulated antiretroviral therapy: interest and attitudes of HIV-infected patients","volume":"8","author":"Williams","year":"2013","journal-title":"Nanomedicine (Lond.)"},{"key":"10.1016\/j.tim.2019.02.009_bb0035","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1002690","article-title":"Safety, tolerability, and pharmacokinetics of long-acting injectable cabotegravir in low-risk HIV-uninfected individuals: HPTN 077, a phase 2a randomized controlled trial","volume":"15","author":"Landovitz","year":"2018","journal-title":"PLoS Med."},{"key":"10.1016\/j.tim.2019.02.009_bb0040","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.1016\/S1473-3099(15)00152-8","article-title":"Cabotegravir plus rilpivirine, once a day, after induction with cabotegravir plus nucleoside reverse transcriptase inhibitors in antiretroviral-naive adults with HIV-1 infection (LATTE): a randomised, phase 2b, dose-ranging trial","volume":"15","author":"Margolis","year":"2015","journal-title":"Lancet Infect. Dis."},{"key":"10.1016\/j.tim.2019.02.009_bb0045","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.1126\/science.1248707","article-title":"Long-acting integrase inhibitor protects macaques from intrarectal simian\/human immunodeficiency virus","volume":"343","author":"Andrews","year":"2014","journal-title":"Science"},{"key":"10.1016\/j.tim.2019.02.009_bb0050","first-page":"3393","article-title":"Comparative manufacture and cell-based delivery of antiretroviral nanoformulations","volume":"6","author":"Balkundi","year":"2011","journal-title":"Int. J. Nanomedicine"},{"key":"10.1016\/j.tim.2019.02.009_bb0055","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0145966","article-title":"Cellular responses and tissue depots for nanoformulated antiretroviral therapy","volume":"10","author":"Martinez-Skinner","year":"2015","journal-title":"PLoS One"},{"key":"10.1016\/j.tim.2019.02.009_bb0060","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1016\/j.jconrel.2010.11.019","article-title":"Analyses of nanoformulated antiretroviral drug charge, size, shape and content for uptake, drug release and antiviral activities in human monocyte-derived macrophages","volume":"150","author":"Nowacek","year":"2011","journal-title":"J. Control. Release"},{"key":"10.1016\/j.tim.2019.02.009_bb0065","doi-asserted-by":"crossref","first-page":"1263","DOI":"10.1016\/j.nano.2013.05.003","article-title":"Macrophage folate receptor-targeted antiretroviral therapy facilitates drug entry, retention, antiretroviral activities and biodistribution for reduction of human immunodeficiency virus infections","volume":"9","author":"Puligujja","year":"2013","journal-title":"Nanomedicine"},{"key":"10.1016\/j.tim.2019.02.009_bb0070","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1016\/j.jconrel.2018.12.027","article-title":"Nanoencapsulation introduces long-acting phenomenon to tenofovir alafenamide and emtricitabine drug combination: a comparative pre-exposure prophylaxis efficacy study against HIV-1 vaginal transmission","volume":"294","author":"Mandal","year":"2018","journal-title":"J. Control. Release"},{"key":"10.1016\/j.tim.2019.02.009_bb0075","first-page":"1281","article-title":"Long-acting slow effective release antiretroviral therapy. Expert Opin","volume":"14","author":"Edagwa","year":"2017","journal-title":"Drug Deliv."},{"key":"10.1016\/j.tim.2019.02.009_bb0080","doi-asserted-by":"crossref","first-page":"e75","DOI":"10.1097\/QAI.0000000000001170","article-title":"Creation of a long-acting nanoformulated 2\u2032,3\u2032-dideoxy-3\u2032-thiacytidine","volume":"74","author":"Guo","year":"2016","journal-title":"J. Acquir. Immune Defic. Syndr."},{"key":"10.1016\/j.tim.2019.02.009_bb0085","first-page":"443","article-title":"Creation of a long-acting nanoformulated dolutegravir. Nat","volume":"9","author":"Sillman","year":"2018","journal-title":"Commun."},{"key":"10.1016\/j.tim.2019.02.009_bb0090","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.biomaterials.2017.10.023","article-title":"Creation of a nanoformulated cabotegravir prodrug with improved antiretroviral profiles","volume":"151","author":"Zhou","year":"2018","journal-title":"Biomaterials"},{"key":"10.1016\/j.tim.2019.02.009_bb0095","doi-asserted-by":"crossref","first-page":"8371","DOI":"10.1039\/C8CC04708A","article-title":"ProTide generated long-acting abacavir nanoformulations","volume":"54","author":"Lin","year":"2018","journal-title":"Chem. Commun. (Camb.)"},{"key":"10.1016\/j.tim.2019.02.009_bb0100","doi-asserted-by":"crossref","first-page":"82","DOI":"10.18433\/J3X61S","article-title":"Prodrugs of antiinfective agents: a review","volume":"19","author":"Piplani","year":"2016","journal-title":"J. Pharm. Pharm. Sci."},{"key":"10.1016\/j.tim.2019.02.009_bb0105","first-page":"e01316","article-title":"Pharmacokinetics of a long-acting nanoformulated dolutegravir prodrug in rhesus macaques","volume":"62","author":"McMillan","year":"2017","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.tim.2019.02.009_bb0110","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1097\/QAD.0000000000002032","article-title":"Pharmacokinetic testing of a first generation cabotegravir prodrug in rhesus macaques","volume":"33","author":"McMillan","year":"2019","journal-title":"AIDS"},{"key":"10.1016\/j.tim.2019.02.009_bb0115","doi-asserted-by":"crossref","first-page":"1913","DOI":"10.2217\/nnm-2016-0164","article-title":"Development and characterization of a long-acting nanoformulated abacavir prodrug","volume":"11","author":"Singh","year":"2016","journal-title":"Nanomedicine (Lond.)"},{"key":"10.1016\/j.tim.2019.02.009_bb0120","doi-asserted-by":"crossref","first-page":"871","DOI":"10.2217\/nnm-2017-0381","article-title":"Optimizing the preparation and stability of decorated antiretroviral drug nanocrystals","volume":"13","author":"Zhou","year":"2018","journal-title":"Nanomedicine (Lond.)"},{"key":"10.1016\/j.tim.2019.02.009_bb0125","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1097\/COH.0000000000000168","article-title":"Formulation and pharmacology of long-acting cabotegravir","volume":"10","author":"Trezza","year":"2015","journal-title":"Curr. Opin. HIV AIDS"},{"key":"10.1016\/j.tim.2019.02.009_bb0130","doi-asserted-by":"crossref","first-page":"2042","DOI":"10.1128\/AAC.01529-09","article-title":"Pharmacokinetics and disposition of rilpivirine (TMC278) nanosuspension as a long-acting injectable antiretroviral formulation","volume":"54","author":"van \u2019t Klooster","year":"2010","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.tim.2019.02.009_bb0135","doi-asserted-by":"crossref","first-page":"1468","DOI":"10.1016\/S0140-6736(17)31962-1","article-title":"Long-acting injectable ART: next revolution in HIV?","volume":"390","author":"Boyd","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.tim.2019.02.009_bb0140","doi-asserted-by":"crossref","first-page":"e331","DOI":"10.1016\/S2352-3018(17)30068-1","article-title":"Safety and tolerability of long-acting cabotegravir injections in HIV-uninfected men (ECLAIR): a multicentre, double-blind, randomised, placebo-controlled, phase 2a trial","volume":"4","author":"Markowitz","year":"2017","journal-title":"Lancet HIV"},{"key":"10.1016\/j.tim.2019.02.009_bb0145","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.01058-18","article-title":"Extended-duration MK-8591-eluting implant as a candidate for HIV treatment and prevention","volume":"62","author":"Barrett","year":"2018","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.tim.2019.02.009_bb0150","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1097\/COH.0000000000000470","article-title":"Antiretroviral implants for treatment and prevention of HIV infection","volume":"13","author":"Flexner","year":"2018","journal-title":"Curr. Opin. HIV AIDS"},{"key":"10.1016\/j.tim.2019.02.009_bb0155","doi-asserted-by":"crossref","first-page":"3913","DOI":"10.1128\/AAC.00656-15","article-title":"Pharmacokinetics of long-acting tenofovir alafenamide (GS-7340) subdermal implant for HIV prophylaxis","volume":"59","author":"Gunawardana","year":"2015","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.tim.2019.02.009_bb0160","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1097\/COH.0000000000000467","article-title":"4\u2032-Ethynyl-2-fluoro-2\u2032-deoxyadenosine, MK-8591: a novel HIV-1 reverse transcriptase translocation inhibitor","volume":"13","author":"Markowitz","year":"2018","journal-title":"Curr. Opin. HIV AIDS"},{"key":"10.1016\/j.tim.2019.02.009_bb0165","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1002655","article-title":"Safety and pharmacokinetics of single, dual, and triple antiretroviral drug formulations delivered by pod-intravaginal rings designed for HIV-1 prevention: a Phase I trial","volume":"15","author":"Vincent","year":"2018","journal-title":"PLoS Med."},{"key":"10.1016\/j.tim.2019.02.009_bb0170","doi-asserted-by":"crossref","first-page":"2477","DOI":"10.1093\/jac\/dku160","article-title":"Pre-clinical development of a combination microbicide vaginal ring containing dapivirine and darunavir","volume":"69","author":"Murphy","year":"2014","journal-title":"J. Antimicrob. Chemother."},{"key":"10.1016\/j.tim.2019.02.009_bb0175","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/j.ejps.2009.11.007","article-title":"Segmented polyurethane intravaginal rings for the sustained combined delivery of antiretroviral agents dapivirine and tenofovir","volume":"39","author":"Johnson","year":"2010","journal-title":"Eur. J. Pharm. Sci."},{"key":"10.1016\/j.tim.2019.02.009_bb0180","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1016\/j.ejps.2012.12.002","article-title":"A silicone elastomer vaginal ring for HIV prevention containing two microbicides with different mechanisms of action","volume":"48","author":"Fetherston","year":"2013","journal-title":"Eur. J. Pharm. Sci."},{"key":"10.1016\/j.tim.2019.02.009_bb0185","article-title":"Phase 2a safety, pharmacokinetics, and acceptability of dapivirine vaginal rings in US postmenopausal women","author":"Chen","year":"2018","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.tim.2019.02.009_bb0190","doi-asserted-by":"crossref","first-page":"2121","DOI":"10.1056\/NEJMoa1506110","article-title":"Use of a vaginal ring containing dapivirine for HIV-1 prevention in women","volume":"375","author":"Baeten","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.tim.2019.02.009_bb0195","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1097\/QAI.0000000000000702","article-title":"Phase 1 safety, pharmacokinetics, and pharmacodynamics of dapivirine and maraviroc vaginal rings: a double-blind randomized trial","volume":"70","author":"Chen","year":"2015","journal-title":"J. Acquir. Immune Defic. Syndr."},{"key":"10.1016\/j.tim.2019.02.009_bb0200","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1089\/aid.2016.0040","article-title":"Comparison of dapivirine vaginal gel and film formulation pharmacokinetics and pharmacodynamics (FAME 02B)","volume":"33","author":"Robinson","year":"2017","journal-title":"AIDS Res. Hum. Retrovir."},{"key":"10.1016\/j.tim.2019.02.009_bb0205","doi-asserted-by":"crossref","first-page":"S3","DOI":"10.1016\/j.antiviral.2013.09.025","article-title":"Development of dapivirine vaginal ring for HIV prevention","volume":"100","author":"Devlin","year":"2013","journal-title":"Antivir. Res."},{"key":"10.1016\/j.tim.2019.02.009_bb0210","doi-asserted-by":"crossref","first-page":"4156","DOI":"10.1038\/s41467-018-06490-w","article-title":"Ultra-long-acting removable drug delivery system for HIV treatment and prevention","volume":"9","author":"Kovarova","year":"2018","journal-title":"Nat. Commun."},{"key":"10.1016\/j.tim.2019.02.009_bb0215","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/S0378-5173(00)00568-8","article-title":"Myotoxicity studies of injectable biodegradable in-situ forming drug delivery systems","volume":"212","author":"Kranz","year":"2001","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.tim.2019.02.009_bb0220","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1177\/0885328217739451","article-title":"Dynamic mechanical behaviour of nanoparticle loaded biodegradable PVA films for vaginal drug delivery","volume":"32","author":"Traore","year":"2018","journal-title":"J. Biomater. Appl."},{"key":"10.1016\/j.tim.2019.02.009_bb0225","doi-asserted-by":"crossref","first-page":"88","DOI":"10.2174\/157016212799304599","article-title":"Formulation and delivery of microbicides","volume":"10","author":"Agashe","year":"2012","journal-title":"Curr. HIV Res."},{"key":"10.1016\/j.tim.2019.02.009_bb0230","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1002\/adhm.201300280","article-title":"Antiretroviral solid drug nanoparticles with enhanced oral bioavailability: production, characterization, and in vitro-in vivo correlation","volume":"3","author":"McDonald","year":"2014","journal-title":"Adv. Healthc. Mater."},{"key":"10.1016\/j.tim.2019.02.009_bb0235","article-title":"Improving maraviroc oral bioavailability by formation of solid drug nanoparticles","author":"Savage","year":"2018","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"10.1016\/j.tim.2019.02.009_bb0240","doi-asserted-by":"crossref","DOI":"10.1038\/ncomms13184","article-title":"Accelerated oral nanomedicine discovery from miniaturized screening to clinical production exemplified by paediatric HIV nanotherapies","volume":"7","author":"Giardiello","year":"2016","journal-title":"Nat. Commun."},{"key":"10.1016\/j.tim.2019.02.009_bb0245","doi-asserted-by":"crossref","first-page":"1639","DOI":"10.2217\/nnm.12.181","article-title":"Surface-stabilized lopinavir nanoparticles enhance oral bioavailability without coadministration of ritonavir","volume":"8","author":"Jain","year":"2013","journal-title":"Nanomedicine (Lond.)"},{"key":"10.1016\/j.tim.2019.02.009_bb0250","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1016\/j.actbio.2018.04.045","article-title":"Nanoparticle-in-microparticle oral drug delivery system of a clinically relevant darunavir\/ritonavir antiretroviral combination","volume":"74","author":"Augustine","year":"2018","journal-title":"Acta Biomater."},{"key":"10.1016\/j.tim.2019.02.009_bb0255","first-page":"2","article-title":"Development of an oral once-weekly drug delivery system for HIV antiretroviral therapy. Nat","volume":"9","author":"Kirtane","year":"2018","journal-title":"Commun."},{"key":"10.1016\/j.tim.2019.02.009_bb0260","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1097\/COH.0000000000000466","article-title":"Dolutegravir-rilpivirine coformulation","volume":"13","author":"Sun","year":"2018","journal-title":"Curr. Opin. HIV AIDS"},{"key":"10.1016\/j.tim.2019.02.009_bb0265","article-title":"Recent developments of nanotherapeutics for targeted and long-acting, combination HIV chemotherapy","author":"Gao","year":"2018","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"10.1016\/j.tim.2019.02.009_bb0270","doi-asserted-by":"crossref","first-page":"2463","DOI":"10.1097\/QAD.0000000000001969","article-title":"Extended cell and plasma drug levels after one dose of a three-in-one nanosuspension containing lopinavir, efavirenz, and tenofovir in nonhuman primates","volume":"32","author":"Koehn","year":"2018","journal-title":"AIDS"},{"key":"10.1016\/j.tim.2019.02.009_bb0275","doi-asserted-by":"crossref","first-page":"1787","DOI":"10.1016\/j.xphs.2018.03.005","article-title":"Long-acting profile of 4 drugs in 1 Anti-HIV nanosuspension in nonhuman primates for 5 weeks after a single subcutaneous injection","volume":"107","author":"McConnachie","year":"2018","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.tim.2019.02.009_bb0280","doi-asserted-by":"crossref","first-page":"3153","DOI":"10.1016\/j.xphs.2018.07.032","article-title":"Three HIV drugs, atazanavir, ritonavir, and tenofovir, coformulated in drug-combination nanoparticles exhibit long-acting and lymphocyte-targeting properties in nonhuman primates","volume":"107","author":"Perazzolo","year":"2018","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.tim.2019.02.009_bb0285","doi-asserted-by":"crossref","first-page":"7510","DOI":"10.1128\/AAC.04108-14","article-title":"Pharmacokinetics, biodistribution, and toxicity of folic acid-coated antiretroviral nanoformulations","volume":"58","author":"Gautam","year":"2014","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.tim.2019.02.009_bb0290","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/j.biomaterials.2014.11.012","article-title":"Pharmacodynamics of long-acting folic acid-receptor targeted ritonavir-boosted atazanavir nanoformulations","volume":"41","author":"Puligujja","year":"2015","journal-title":"Biomaterials"},{"key":"10.1016\/j.tim.2019.02.009_bb0295","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1016\/j.ejpb.2014.11.021","article-title":"Stealth anti-CD4 conjugated immunoliposomes with dual antiretroviral drugs \u2013 modern Trojan horses to combat HIV","volume":"89","author":"Ramana","year":"2015","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"10.1016\/j.tim.2019.02.009_bb0300","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1124\/jpet.117.247288","article-title":"Antiretroviral drug metabolism in humanized PXR-CAR-CYP3A-NOG mice","volume":"365","author":"McMillan","year":"2018","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.tim.2019.02.009_bb0305","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1007\/s11481-010-9198-7","article-title":"Nanoformulated antiretroviral drug combinations extend drug release and antiretroviral responses in HIV-1-infected macrophages: implications for neuroAIDS therapeutics","volume":"5","author":"Nowacek","year":"2010","journal-title":"J. NeuroImmune Pharmacol."},{"key":"10.1016\/j.tim.2019.02.009_bb0310","doi-asserted-by":"crossref","first-page":"903","DOI":"10.2217\/nnm.09.71","article-title":"NanoART synthesis, characterization, uptake, release and toxicology for human monocyte-macrophage drug delivery","volume":"4","author":"Nowacek","year":"2009","journal-title":"Nanomedicine (Lond.)"},{"key":"10.1016\/j.tim.2019.02.009_bb0315","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1016\/j.jpba.2018.02.036","article-title":"Simultaneous quantification of intracellular lamivudine and abacavir triphosphate metabolites by LC-MS\/MS","volume":"153","author":"Gautam","year":"2018","journal-title":"J. Pharm. Biomed. Anal."},{"key":"10.1016\/j.tim.2019.02.009_bb0320","doi-asserted-by":"crossref","first-page":"3110","DOI":"10.1128\/AAC.00267-13","article-title":"Preclinical pharmacokinetics and tissue distribution of long-acting nanoformulated antiretroviral therapy","volume":"57","author":"Gautam","year":"2013","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.tim.2019.02.009_bb0325","doi-asserted-by":"crossref","first-page":"2135","DOI":"10.1097\/QAD.0b013e328357f5ad","article-title":"Long-acting nanoformulated antiretroviral therapy elicits potent antiretroviral and neuroprotective responses in HIV-1-infected humanized mice","volume":"26","author":"Dash","year":"2012","journal-title":"AIDS"},{"key":"10.1016\/j.tim.2019.02.009_bb0330","doi-asserted-by":"crossref","first-page":"1577","DOI":"10.1093\/infdis\/jis395","article-title":"Pharmacodynamic and antiretroviral activities of combination nanoformulated antiretrovirals in HIV-1-infected human peripheral blood lymphocyte-reconstituted mice","volume":"206","author":"Roy","year":"2012","journal-title":"J. Infect. Dis."},{"key":"10.1016\/j.tim.2019.02.009_bb0335","article-title":"Nanoformulated antiretroviral therapy attenuates brain metabolic oxidative stress","author":"Montenegro-Burke","year":"2018","journal-title":"Mol. Neurobiol."},{"key":"10.1016\/j.tim.2019.02.009_bb0340","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1038\/nrd.2018.46","article-title":"The expanding role of prodrugs in contemporary drug design and development","volume":"17","author":"Rautio","year":"2018","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.tim.2019.02.009_bb0345","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1038\/nrd2468","article-title":"Prodrugs: design and clinical applications","volume":"7","author":"Rautio","year":"2008","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.tim.2019.02.009_bb0350","doi-asserted-by":"crossref","first-page":"2265","DOI":"10.2174\/156802611797183230","article-title":"Prodrugs \u2013 an efficient way to breach delivery and targeting barriers","volume":"11","author":"Huttunen","year":"2011","journal-title":"Curr. Top. Med. Chem."},{"key":"10.1016\/j.tim.2019.02.009_bb0355","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1208\/s12248-012-9446-2","article-title":"Dose selection based on physiologically based pharmacokinetic (PBPK) approaches","volume":"15","author":"Jones","year":"2013","journal-title":"AAPS J."},{"key":"10.1016\/j.tim.2019.02.009_bb0360","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1016\/j.apsb.2016.04.004","article-title":"PBPK modeling and simulation in drug research and development","volume":"6","author":"Zhuang","year":"2016","journal-title":"Acta Pharm. Sin. B"},{"key":"10.1016\/j.tim.2019.02.009_bb0365","doi-asserted-by":"crossref","DOI":"10.1002\/psp4.13","article-title":"Physiologically based pharmacokinetic modeling of fluorescently labeled block copolymer nanoparticles for controlled drug delivery in leukemia therapy","volume":"4","author":"Gilkey","year":"2015","journal-title":"CPT Pharmacometrics Syst. Pharmacol."},{"key":"10.1016\/j.tim.2019.02.009_bb0370","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1208\/s12248-016-0010-3","article-title":"Physiologically based pharmacokinetic (PBPK) modeling of pharmaceutical nanoparticles","volume":"19","author":"Li","year":"2017","journal-title":"AAPS J."},{"key":"10.1016\/j.tim.2019.02.009_bb0375","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1038\/nbt.3330","article-title":"Principles of nanoparticle design for overcoming biological barriers to drug delivery","volume":"33","author":"Blanco","year":"2015","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.tim.2019.02.009_bb0380","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1002\/adhm.201200084","article-title":"Fluorescence-tagged gold nanoparticles for rapidly characterizing the size-dependent biodistribution in tumor models","volume":"1","author":"Chou","year":"2012","journal-title":"Adv. Healthc. Mater."},{"key":"10.1016\/j.tim.2019.02.009_bb0385","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0169-409X(99)00036-8","article-title":"The pharmacokinetics of liposomes in tumor targeting","volume":"40","author":"Harashima","year":"1999","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.tim.2019.02.009_bb0390","doi-asserted-by":"crossref","first-page":"128","DOI":"10.3109\/17435390.2013.863406","article-title":"Physiologically based pharmacokinetic modeling of polyethylene glycol-coated polyacrylamide nanoparticles in rats","volume":"8","author":"Li","year":"2014","journal-title":"Nanotoxicology"},{"key":"10.1016\/j.tim.2019.02.009_bb0395","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1007\/s40262-014-0227-1","article-title":"Physiologically based pharmacokinetic modelling to inform development of intramuscular long-acting nanoformulations for HIV","volume":"54","author":"Rajoli","year":"2015","journal-title":"Clin. Pharmacokinet."},{"key":"10.1016\/j.tim.2019.02.009_bb0400","doi-asserted-by":"crossref","first-page":"3838","DOI":"10.1128\/AAC.00094-16","article-title":"Validation of computational approaches for antiretroviral dose optimization","volume":"60","author":"Siccardi","year":"2016","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.tim.2019.02.009_bb0405","article-title":"Predicting drug\u2013drug interactions between rifampicin and long-acting cabotegravir and rilpivirine using PBPK modelling","author":"Rajoli","year":"2018","journal-title":"J. Infect. Dis."},{"key":"10.1016\/j.tim.2019.02.009_bb0410","doi-asserted-by":"crossref","DOI":"10.1155\/2012\/852384","article-title":"Cutting edge PBPK models and analyses: providing the basis for future modeling efforts and bridges to emerging toxicology paradigms","volume":"2012","author":"Caldwell","year":"2012","journal-title":"J. Toxicol."},{"key":"10.1016\/j.tim.2019.02.009_bb0415","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1002\/cpt.37","article-title":"Physiologically based pharmacokinetic modeling in drug discovery and development: a pharmaceutical industry perspective","volume":"97","author":"Jones","year":"2015","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.tim.2019.02.009_bb0420","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1517\/17425255.2011.585968","article-title":"Have physiologically-based pharmacokinetic models delivered?","volume":"7","author":"Edginton","year":"2011","journal-title":"Expert Opin. Drug Metab. Toxicol."},{"key":"10.1016\/j.tim.2019.02.009_bb0425","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1002\/(SICI)1520-6017(200001)89:1<16::AID-JPS3>3.0.CO;2-E","article-title":"A priori prediction of tissue:plasma partition coefficients of drugs to facilitate the use of physiologically-based pharmacokinetic models in drug discovery","volume":"89","author":"Poulin","year":"2000","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.tim.2019.02.009_bb0430","doi-asserted-by":"crossref","first-page":"1950","DOI":"10.1111\/bcp.13625","article-title":"Physiologically-based pharmacokinetic model of vaginally administered dapivirine ring and film formulations","volume":"84","author":"Kay","year":"2018","journal-title":"Br. J. Clin. Pharmacol."},{"key":"10.1016\/j.tim.2019.02.009_bb0435","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1002\/bdd.1810","article-title":"Absolute abundance and function of intestinal drug transporters: a prerequisite for fully mechanistic in vitro-in vivo extrapolation of oral drug absorption","volume":"34","author":"Harwood","year":"2013","journal-title":"Biopharm. Drug Dispos."},{"key":"10.1016\/j.tim.2019.02.009_bb0440","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1002\/bdd.1996","article-title":"A physiologically based pharmacokinetic model to predict the pharmacokinetics of highly protein-bound drugs and the impact of errors in plasma protein binding","volume":"37","author":"Ye","year":"2016","journal-title":"Biopharm. Drug Dispos."},{"key":"10.1016\/j.tim.2019.02.009_bb0445","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1016\/j.addr.2018.06.016","article-title":"The emerging role of physiologically based pharmacokinetic modelling in solid drug nanoparticle translation","volume":"131","author":"Siccardi","year":"2018","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.tim.2019.02.009_bb0450","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1016\/j.carbpol.2016.10.015","article-title":"Hyaluronic acid-coated nanoparticles for targeted photodynamic therapy of cancer guided by near-infrared and MR imaging","volume":"157","author":"Park","year":"2017","journal-title":"Carbohydr. Polym."},{"key":"10.1016\/j.tim.2019.02.009_bb0455","doi-asserted-by":"crossref","first-page":"1919","DOI":"10.2967\/jnumed.114.146019","article-title":"Theranostic nanoparticles","volume":"55","author":"Chen","year":"2014","journal-title":"J. Nucl. Med."},{"key":"10.1016\/j.tim.2019.02.009_bb0460","doi-asserted-by":"crossref","first-page":"256","DOI":"10.7150\/thno.22764","article-title":"Multimodal theranostic nanoformulations permit magnetic resonance bioimaging of antiretroviral drug particle tissue-cell biodistribution","volume":"8","author":"Kevadiya","year":"2018","journal-title":"Theranostics"},{"key":"10.1016\/j.tim.2019.02.009_bb0465","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1016\/j.biomaterials.2018.09.018","article-title":"Bioimaging predictors of rilpivirine biodistribution and antiretroviral activities","volume":"185","author":"Ottemann","year":"2018","journal-title":"Biomaterials"},{"key":"10.1016\/j.tim.2019.02.009_bb0470","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1021\/ar400086e","article-title":"Multifunctional compact hybrid Au nanoshells: a new generation of nanoplasmonic probes for biosensing, imaging, and controlled release","volume":"47","author":"Jin","year":"2014","journal-title":"Acc. Chem. Res."},{"key":"10.1016\/j.tim.2019.02.009_bb0475","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1016\/j.msec.2017.05.029","article-title":"Biodistribution and in vivo performance of fattigation-platform theranostic nanoparticles","volume":"79","author":"Tran","year":"2017","journal-title":"Mater. Sci. Eng. C Mater. Biol. Appl."},{"key":"10.1016\/j.tim.2019.02.009_bb0480","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1097\/COH.0000000000000379","article-title":"Candidates for inclusion in a universal antiretroviral regimen: tenofovir alafenamide","volume":"12","author":"Gotham","year":"2017","journal-title":"Curr. Opin. HIV AIDS"},{"key":"10.1016\/j.tim.2019.02.009_bb0485","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/j.jconrel.2018.04.042","article-title":"Ignoring the modeling approaches: towards the shadowy paths in nanomedicine","volume":"280","author":"Hassanzadeh","year":"2018","journal-title":"J. Control. Release"},{"key":"10.1016\/j.tim.2019.02.009_bb0490","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1080\/1061186X.2017.1419363","article-title":"Translation of combination nanodrugs into nanomedicines: lessons learned and future outlook","volume":"26","author":"Mu","year":"2018","journal-title":"J. Drug Target."},{"key":"10.1016\/j.tim.2019.02.009_bb0495","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1016\/j.nano.2015.12.376","article-title":"Challenges of clinical translation in nanomedicine: a qualitative study","volume":"12","author":"Satalkar","year":"2016","journal-title":"Nanomedicine"},{"key":"10.1016\/j.tim.2019.02.009_bb0500","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/j.jconrel.2011.09.063","article-title":"Drug targeting to tumors: principles, pitfalls and (pre-) clinical progress","volume":"161","author":"Lammers","year":"2012","journal-title":"J. Control. Release"},{"key":"10.1016\/j.tim.2019.02.009_bb0505","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1016\/j.bbrc.2015.08.023","article-title":"Regulatory aspects on nanomedicines","volume":"468","author":"Sainz","year":"2015","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.tim.2019.02.009_bb0510","doi-asserted-by":"crossref","first-page":"2282","DOI":"10.1021\/pr400185w","article-title":"Functional proteome of macrophage carried nanoformulated antiretroviral therapy demonstrates enhanced particle carrying capacity","volume":"12","author":"Martinez-Skinner","year":"2013","journal-title":"J. Proteome Res."},{"key":"10.1016\/j.tim.2019.02.009_bb0515","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1186\/s12977-014-0133-5","article-title":"Opposing regulation of endolysosomal pathways by long-acting nanoformulated antiretroviral therapy and HIV-1 in human macrophages","volume":"12","author":"Arainga","year":"2015","journal-title":"Retrovirology"},{"key":"10.1016\/j.tim.2019.02.009_bb0520","doi-asserted-by":"crossref","first-page":"9504","DOI":"10.1128\/JVI.01557-14","article-title":"Endosomal trafficking of nanoformulated antiretroviral therapy facilitates drug particle carriage and HIV clearance","volume":"88","author":"Guo","year":"2014","journal-title":"J. Virol."},{"key":"10.1016\/j.tim.2019.02.009_bb0525","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1172\/JCI90025","article-title":"Autophagy facilitates macrophage depots of sustained-release nanoformulated antiretroviral drugs","volume":"127","author":"Gnanadhas","year":"2017","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.tim.2019.02.009_bb0530","doi-asserted-by":"crossref","DOI":"10.1038\/srep23513","article-title":"HIV-1 cellular and tissue replication patterns in infected humanized mice","volume":"6","author":"Arainga","year":"2016","journal-title":"Sci. Rep."},{"key":"10.1016\/j.tim.2019.02.009_bb0535","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1016\/B978-0-12-416020-0.00014-0","article-title":"Cell delivery of therapeutic nanoparticles","volume":"104","author":"McMillan","year":"2011","journal-title":"Prog. Mol. Biol. Transl. Sci."},{"key":"10.1016\/j.tim.2019.02.009_bb0540","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.addr.2016.04.025","article-title":"Challenges and strategies in anti-cancer nanomedicine development: an industry perspective","volume":"108","author":"Hare","year":"2017","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.tim.2019.02.009_bb0545","doi-asserted-by":"crossref","first-page":"790","DOI":"10.3389\/fphar.2018.00790","article-title":"Current trends and challenges in the clinical translation of nanoparticulate nanomedicines: pathways for translational development and commercialization","volume":"9","author":"Hua","year":"2018","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.tim.2019.02.009_bb0550","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1016\/j.cossms.2012.10.001","article-title":"Clinical translation of nanomedicines","volume":"16","author":"Svenson","year":"2012","journal-title":"Curr. Opin. Solid State Mater. Sci."},{"key":"10.1016\/j.tim.2019.02.009_bb0555","doi-asserted-by":"crossref","first-page":"3867","DOI":"10.1002\/jps.23691","article-title":"Pharmaceutical development and regulatory considerations for nanoparticles and nanoparticulate drug delivery systems","volume":"102","author":"Narang","year":"2013","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.tim.2019.02.009_bb0560","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1146\/annurev-virology-101416-041703","article-title":"Humanized mouse models for human immunodeficiency virus infection","volume":"4","author":"Marsden","year":"2017","journal-title":"Annu. Rev. Virol."},{"key":"10.1016\/j.tim.2019.02.009_bb0565","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/j.coviro.2017.07.027","article-title":"Humanized mouse models of latent HIV infection","volume":"25","author":"Deruaz","year":"2017","journal-title":"Curr. Opin. Virol."},{"key":"10.1016\/j.tim.2019.02.009_bb0570","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1007\/s11481-011-9335-y","article-title":"Can humanized mice reflect the complex pathobiology of HIV-associated neurocognitive disorders?","volume":"7","author":"Gorantla","year":"2012","journal-title":"J. NeuroImmune Pharmacol."},{"key":"10.1016\/j.tim.2019.02.009_bb0575","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1016\/j.meegid.2016.07.012","article-title":"Non-human primates in HIV research: achievements, limits and alternatives","volume":"46","author":"Garcia-Tellez","year":"2016","journal-title":"Infect. Genet. Evol."},{"key":"10.1016\/j.tim.2019.02.009_bb0580","article-title":"Recent advances in pre-exposure prophylaxis for HIV","volume":"359","author":"Desai","year":"2017","journal-title":"BMJ"},{"key":"10.1016\/j.tim.2019.02.009_bb0585","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1007\/s13365-018-0616-6","article-title":"An SIV macaque model of SIV and HAND: the need for adjunctive therapies in HIV that target activated monocytes and macrophages","volume":"24","author":"Mallard","year":"2018","journal-title":"J. Neurovirol."},{"key":"10.1016\/j.tim.2019.02.009_bb0590","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1007\/978-3-642-10324-7_2","article-title":"Species differences in pharmacokinetics and pharmacodynamics","volume":"199","author":"Toutain","year":"2010","journal-title":"Handb. Exp. Pharmacol."},{"key":"10.1016\/j.tim.2019.02.009_bb0595","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1293\/tox.2016-0075","article-title":"The lymphoid system: a review of species differences","volume":"30","author":"Haley","year":"2017","journal-title":"J. Toxicol. Pathol."}],"container-title":["Trends in Microbiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0966842X19300605?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0966842X19300605?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,18]],"date-time":"2025-10-18T18:39:50Z","timestamp":1760812790000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0966842X19300605"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,7]]},"references-count":119,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2019,7]]}},"alternative-id":["S0966842X19300605"],"URL":"https:\/\/doi.org\/10.1016\/j.tim.2019.02.009","relation":{},"ISSN":["0966-842X"],"issn-type":[{"value":"0966-842X","type":"print"}],"subject":[],"published":{"date-parts":[[2019,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The Promise of Long-Acting Antiretroviral Therapies: From Need to Manufacture","name":"articletitle","label":"Article Title"},{"value":"Trends in Microbiology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.tim.2019.02.009","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}